Longitudinal Proteomic Signatures of Dupilumab and Tralokinumab Treated Atopic Dermatitis Patients

Wojciech Francuzik, Kristijan Pažur, Margitta Worm · 2026

Read Longitudinal Proteomic Signatures of Dupilumab and Tralokinumab Treated Atopic Dermatitis Patients by Wojciech Francuzik, Kristijan Pažur, Margitta Worm (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13612374.txt.

Description

Wojciech Francuzik, Kristijan Pažur, and Margitta Worm track blood proteins in eczema patients on two biologic drugs, in a paper dated twenty twenty-six. Ten patients took dupilumab and ten took tralokinumab for twelve months. Blood samples came at the start and after a year of care.

A 440-protein panel mapped each patient's pattern against healthy controls. Both drugs shrank the core allergy-type swelling signal, cutting marker CCL17. Dupilumab shifted a broader set, lifting proteins of the other immune arm. The drugs pushed some repair and metabolism proteins in opposite ways.

Catalog record

CREATORWojciech Francuzik, Kristijan Pažur, Margitta Worm
YEAR2026
COLLECTIONPAPERS
FORMATTXT
FILE SIZE33 KB
VERSION1.0
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC13612374

Browse the full library · About the Tower of Babel